{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Serious AE-Lung Infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Serious AE-Treatment-related secondary malignancy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Serious AE-Respiratory Disorders including respiratory failures"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Serious AE-other infections"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Toxicity data will be summarized by frequency tables.","groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"throughout study treatment and up to 30 days after completion of study treatment, up to 119 months","title":"Treatment-related Unmanageable Toxicities, Including Grade 3 Non-hematologic Effects, or Grade 4 Hematologic Effects","type":"SECONDARY","unitOfMeasure":"Participants"}